Business
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in Q3 2025Strengthened leadership team with key appointments of Leonardo Viana Nicacio, M.D., as Chief Medic
About this update from Protara Therapeutics, Inc.
[{"type":"image","alt":"Protara Therapeutics","displaySize":"","headline":null,"caption":"Protara Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UG_sFiObOKNigh1f.P_1zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72","width":300,"height":106}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":126,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":131,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in Q3 2025","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened leadership team with key appointments of Leonardo Viana Nicacio, M.D., as Chief Medical Officer, and Shane Williams, Ph.D., as VP, Head of Human Resources, Chief People Officer","length":189,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":332,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash, cash equivalents and investments of $158 million as of March 31, 2025, expected to support planned operations into 2027","length":125,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":125,"olType":false},{"type":"text","content":"NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.","length":308,"tagName":"p"},{"type":"text","content":"“We have made significant progress thus far in 2025, notably with the rece...